A true theranostic pair - ^44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer.

Abstract

This study investigates the theranostic potential of a ^44/47Sc-labeled antagonist targeting the gastrin-releasing peptide receptor (GRPR) in prostate and breast tumors. A statine-based GRPR antagonist (AAZTA⁵-Pip-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH₂: LF1) was radiolabeled with scandium-44/47. Detailed in vitro evaluation was carried out in PC3 and T47D cancer cells. In vivo studies, including blood and organ clearance, plasma protein binding, metabolic stability and SPECT/CT imaging, were performed in PC3- and T47D-mice. To assess its therapeutic efficacy, PC3-mice were treated with [⁴⁷Sc]Sc-LF1 either alone or in combination with everolimus. [⁴⁷Sc]Sc-LF1 exhibited high binding affinity, low internalization rate (< 10% in PC3 and T47D cells), and favorable pharmacokinetics, including rapid blood clearance and low plasma protein binding. In PC3-mice, it demonstrated high and specific tumor uptake (45.4 ± 3.9 and 4.9 ± 1.6% I.A./g at 4 and 96 h p.i., respectively), while lower GRPR density in T47D-mice led to reduced uptake (6.1 ± 3.9 and 0.7 ± 0.1% I.A./g at 4 and 72 h p.i.). Its pharmacokinetics enabled high-contrast SPECT/CT imaging in both models. Combined treatment with everolimus and [⁴⁷Sc]Sc-LF1 in PC3-mice, significantly inhibited tumor growth compared to monotherapies. The high tumor uptake in two cancer entities with elevated expression of GRPR and the tumor response (tumor size and survival rate) highlight the significant theranostic potential of [⁴⁴Sc]Sc/[⁴⁷Sc]Sc-LF1 for PET (scandium-44) and SPECT (scandium-47) imaging and radionuclide targeted therapy.